Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Barrientos, JC, O'Brien, S, Brown, JR et al. (25 more authors) (2018) Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma and Leukemia, 18 (12). 803-813.e7. ISSN 2152-2650

Abstract

Metadata

Authors/Creators:
  • Barrientos, JC
  • O'Brien, S
  • Brown, JR
  • Kay, NE
  • Reddy, NM
  • Coutre, S
  • Tam, C
  • Mulligan, S
  • Jaeger, U
  • Devereux, S
  • Pocock, C
  • Robak, T
  • Schuster, SJ
  • Schuh, A
  • Gill, D
  • Bloor, A
  • Dearden, C
  • Moreno, C
  • Cull, G
  • Hamblin, M
  • Jones, JA
  • Eckert, K
  • Solman, IG
  • Suzuki, S
  • Hsu, E
  • James, DF
  • Byrd, JC
  • Hillmen, P https://orcid.org/0000-0001-5617-4403
Copyright, Publisher and Additional Information: © 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Bruton's tyrosine kinase; Disease-related symptoms; Fatigue; Quality of life; Relapsed/refractory CLL/SLL
Dates:
  • Published: December 2018
  • Accepted: 6 August 2018
  • Published (online): 18 August 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Experimental Haematology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 07 Jan 2019 16:30
Last Modified: 07 Jan 2019 16:30
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.clml.2018.08.007

Share / Export

Statistics